Evidence map›Paper›PMID 40817313›Full record

ArticleCommunications medicine2025

Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series.

Ali D Alahmari, Saad Alghamdi, Reem Alasbali, Sara Hisham Samarkandi, Saleh A Alqahtani, Hadeel Samarkandi, Syed Osman Ahmed, Dieter Broering, Hazzaa Alzahrani, Adetola Kassim and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Ali D AlahmariHematology, Stem cell transplant & Cellular therapy department, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia. aalahmari7@kfshrc.edu.sa.
Saad AlghamdiLiver and Small Bowel Health Centre Department, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.
Reem AlasbaliHematology, Stem cell transplant & Cellular therapy department, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.
Sara Hisham SamarkandiHematology, Stem cell transplant & Cellular therapy department, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.
Saleh A AlqahtaniLiver and Small Bowel Health Centre Department, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.ORCID http://orcid.org/0000-0003-2017-3526
Hadeel SamarkandiPharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Kingdom of Saudi Arabia.
Syed Osman AhmedHematology, Stem cell transplant & Cellular therapy department, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.
Dieter BroeringLiver and Small Bowel Health Centre Department, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.
Hazzaa AlzahraniHematology, Stem cell transplant & Cellular therapy department, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.
Adetola KassimDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Mahmoud AljurfHematology, Stem cell transplant & Cellular therapy department, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.
Fahad AlmoharebHematology, Stem cell transplant & Cellular therapy department, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.
Waleed Al-HamoudiLiver and Small Bowel Health Centre Department, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSickle cell disease (SCD) is debilitating, with age-dependent complications such as stroke and liver disease, leading to significant morbidity and early mortality in young adults. Hematopoietic stem cell transplantation (HCT) is curative treatment for SCD, but transplantation-related risks often deter its use, especially in patients with severe comorbidities. A subset of severe SCD patients with significant end-organ dysfunction may benefit from a combined approach of HCT and solid organ transplantation (SOT).

methodsTo the best of our knowledge, this report presents, for the first time, the utilization of dual orthotopic liver transplantation and haploidentical HCT (haplo-HCT) for severe SCD with advanced liver cirrhosis. Employing nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide (PTCy).

resultsBoth patients undergo orthotopic liver transplantation followed by haplo-HCT from the same related donors, achieve stable allograft function, full donor engraftment, and successful immunosuppression withdrawal through immune tolerance induction.

conclusionsDual haplo-HCT and living donor liver transplantation (LDLT) is feasible in eligible SCD patients with end-stage liver disease.

Identifiers

PMID40817313
PMCPMC12356966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.